People with inflammatory bowel disease (IBD) are at significantly higher risk for various forms of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study found. But the reverse wasn’t true: Having SpA was not linked to an increased risk of developing IBD, according to the new analysis, which used genetic…
High blood levels of two microRNAs, a type of small molecule involved in controlling which genes are turned on and off in cells, may predict a poor response to TNF inhibitors in people with ankylosing spondylitis, according to a study in China. While those…
A gene called NAT10 is less active in blood cells from people with new-onset ankylosing spondylitis (AS) than in those from healthy people, suggesting it may serve as a diagnostic biomarker, a study suggests. When combined with higher levels of immune cells called neutrophils,…
Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world analysis of medical records. Although adalimumab (marketed as Humira and biosimilars) was the most commonly prescribed first- and second-line TNF inhibitor, patients stayed with golimumab (marketed…
The levels of circulating cell-free DNA may be a biomarker for assessing disease activity and treatment response in people with ankylosing spondylitis (AS). The study, “Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis”…
Poor sleep quality is highly prevalent among people with axial spondyloarthritis (axSpA) who have moderate to high disease activity and who don’t practice regular physical exercise, a study from Scandinavia reports. More physical activity and greater cardiorespiratory fitness were associated with better sleep. “The extent and magnitude of reduced sleep…
The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective on disease activity, a real-world study has revealed. Further research is needed to better understand these decisions and to optimize axSpA management, according to researchers in the study “…
Two or more comorbidities affected nearly half of the ankylosing spondylitis (AS) patients in a large study of the disease, with the most common coexisting conditions being uveitis (eye inflammation), depression, and hypertension (high blood pressure). Those with no comorbidities were younger and had shorter disease duration, the researchers reported,…
People with ankylosing spondylitis (AS) who report more severe pain and disease activity, and poorer quality of life, continue to work despite their AS — yet their productivity is far less than that of patients whose outcomes are not as severe. That’s according to a new analysis of data…
AVT05, Alvotech’s biosimilar candidate to treat ankylosing spondylitis (AS) and other chronic inflammatory diseases, showed a similar pharmacological profile to the reference medication Simponi (golimumab) in a clinical trial. The Phase 1 trial (NCT05632211) compared the safety, tolerability, and pharmacokinetics — movement into, through, and out…
Get regular updates to your inbox.